ABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial community

ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community.
Formed from the end-August 2022 merger of ABL France into the listed entity without activity ETABLISSEMENTS FAUVET-GIREL (renamed ABL DIAGNOSTICS), the company aims to be part of the Top 3 worldwide players in genotyping of pathogens linked to infectious diseases.

Scroll to Top